Hyundai Pharmaceutical Co Ltd

Hyundai Pharmaceutical Co Ltd maintains a debt-to-equity ratio of 0.61, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is assessed as medium, with a current ratio of 1.13, suggesting it has just enough current assets to cover its current liabilities. However, the company reported negative operating cash flow of -123,285,120 KRW and free cash flow of -9,197,130 KRW, signaling potential short-term liquidity constraints. In terms of profitability, the company's return on equity (ROE) is 3.06%, and its return on assets (ROA) is 1.54%. These figures are below the typical thresholds for strong performance in the pharmaceutical industry, which often sees ROE and ROA in the double-digit range. The company's operating income of 4,160,910,940 KRW and net income of 2,516,256,240 KRW reflect a relatively modest profit margin compared to industry benchmarks. The company's revenue is primarily concentrated in its domestic market, with limited disclosure on geographic diversification. The financial data does not provide a breakdown of revenue by geographic region, making it difficult to assess the extent of international exposure. However, the company's focus on the South Korean market suggests a potential concentration risk if domestic demand fluctuates. Looking at the company's growth trajectory, there is no specific outlook provided for the current or next fiscal year. The company's capital expenditure of -5,864,648,230 KRW indicates a reduction in investment in physical assets, which may suggest a strategic shift or financial constraints. The absence of a clear growth strategy or significant investment in R&D could limit the company's long-term growth potential. The risk assessment highlights a key flag: the company's net cash is negative after subtracting total debt, indicating a potential liquidity risk. The dilution risk is assessed as low, with no immediate pressure for share issuance. However, the company's negative free cash flow and operating cash flow suggest that it may need to seek additional financing in the near term, which could lead to dilution if not managed carefully. Recent events and filings do not provide specific details on the company's strategic initiatives or major developments. The company's financial performance and risk profile suggest a need for careful monitoring of its liquidity and profitability metrics. The absence of recent significant events or strategic announcements indicates a period of relative stability, but also a lack of transformative growth initiatives.